Mane Robert Jonathon, Choi Joanne Jung Eun, Sharpe-Davidson William Fox
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, 310 Great King Street, North Dunedin, Dunedin 9016, New Zealand).
Canterbury District Health Board, Christchurch, New Zealand.
Saudi Dent J. 2021 Dec;33(8):842-852. doi: 10.1016/j.sdentj.2021.09.015. Epub 2021 Sep 13.
Tramadol is an effective alternative local anaesthetic (LA) agent available in dentistry. This review aims to help guide practice by providing clinicians with relevant data regarding adverse effects (AE) associated with locally administered tramadol in the oral environment. A systematic search of three electronic databases was performed to identify relevant studies reporting AE associated with locally administered tramadol in the oral setting. Selected studies were reviewed and included based on inclusion and exclusion criteria. Data collected included: publication year, study design, participant numbers, adverse effects and follow-up duration. Fifteen articles were included comprising of 547 tramadol participants across eight exodontia and seven non-exodontia studies. Thirty-eight associated AE were reported. Nausea was the most commonly reported (4.6%), followed by dizziness (1.3%), vomiting (0.7%) and local erythema (0.4%). No other AE were reported. The prevalence of total AE was similar in ≥ 50 mg tramadol doses (7.2-7.3%); however the total affected number is not dose dependent. The prevalence of AE and affected participants was less when tramadol was used as a sole LA rather than as an adjunct (5.6% vs. 7.9% and 3.4-5.6% vs. 6.3%, respectively). Thus, tramadol is a safe LA agent with a low prevalence of AE when administered in the dental setting.
曲马多是牙科可用的一种有效的局部麻醉替代剂。本综述旨在通过为临床医生提供有关在口腔环境中局部使用曲马多相关不良反应(AE)的相关数据,来帮助指导临床实践。对三个电子数据库进行了系统检索,以识别报告在口腔环境中局部使用曲马多相关AE的相关研究。根据纳入和排除标准对选定的研究进行了审查并纳入。收集的数据包括:发表年份、研究设计、参与者数量、不良反应和随访持续时间。纳入了15篇文章,包括八项拔牙和七项非拔牙研究中的547名曲马多参与者。报告了38例相关AE。恶心是最常报告的(4.6%),其次是头晕(1.3%)、呕吐(0.7%)和局部红斑(0.4%)。未报告其他AE。≥50mg曲马多剂量时总AE的发生率相似(7.2-7.3%);然而,总受影响人数与剂量无关。当曲马多作为单一局部麻醉剂而非辅助剂使用时,AE的发生率和受影响参与者的比例较低(分别为5.6%对7.9%和3.4-5.6%对6.3%)。因此,曲马多在牙科环境中给药时是一种安全的局部麻醉剂,AE发生率较低。